SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards. Its professional team includes translators, terminologists, linguistic engineers, IT experts, technical editors and graphic designers. The Company’s production offices and management departments are located in Argentina, Spain, Uruguay and Panama. The Company offers translations within a range of fields such as legal, financial, business, economy, and health sciences, marketing, advertising and technical. It translates and adapts all of the customer’s software products, such as resource files, online help, printed documentation, including compilation and testing of various components.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-417-8834549
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
SLS International (AMEX:SLS) Frequently Asked Questions
What is SLS International's stock symbol?
SLS International trades on the AMEX under the ticker symbol "SLS."
How were SLS International's earnings last quarter?
SLS International Inc (AMEX:SLS) announced its quarterly earnings data on Thursday, November, 15th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.17. View SLS International's Earnings History.
What price target have analysts set for SLS?
4 brokers have issued 1-year price targets for SLS International's shares. Their forecasts range from $4.00 to $13.00. On average, they anticipate SLS International's share price to reach $7.3333 in the next year. View Analyst Price Targets for SLS International.
What is the consensus analysts' recommendation for SLS International?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SLS International in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SLS International.
What are Wall Street analysts saying about SLS International stock?
Here are some recent quotes from research analysts about SLS International stock:
- 1. Maxim Group analysts commented, "Sellas reported FYE18 with operating expenses of $31.1M which included an impairment charge of $9.6M. Net loss was ($27.7M) and loss attributable to common stockholders was ($41.3M). Sellas ended the year with $5.3M in cash. A warrant exchange in March 2019 could bring in $4.18M. The company still needs to raise capital to support the planned P3 study of galinpepimut-S (GPS) and is currently exploring strategic options, including around nelipepimut-S (NPS) in triple negative breast cancer. We believe the fundamentals remain intact and our positive views around GPS and NPS remain unchanged. That said, we are downgrading to and removing our price target while Sellas addresses its capital needs." (3/22/2019)
- 2. According to Zacks Investment Research, "SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. " (1/16/2019)
Has SLS International been receiving favorable news coverage?
News stories about SLS stock have been trending somewhat negative recently, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SLS International earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days.
What other stocks do shareholders of SLS International own?
Who are SLS International's key executives?
SLS International's management team includes the folowing people:
- Angelos M. Stergiou M.D., President, Chief Executive Officer, Director
- Aleksey N. Krylov, Interim Chief Financial Officer, Treasurer
- Nicholas J. Sarlis M.D. Ph.D., Chief Medical Officer, Senior Vice President
- Gregory M. Torre Ph.D. J.D., Chief Regulatory Officer, Senior Vice President
- John Thomas Burns, Vice President - Finance, Corporate Controller
- Fabio Lopez, Director
- David A. Scheinberg, Director
- Stephen F. Ghiglieri, Independent Director (Age 55)
- Robert L. Van Nostrand, Independent Director
- John Varian, Independent Director
How do I buy shares of SLS International?
Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SLS International's official website?
How can I contact SLS International?
SLS International's mailing address is 3119 S Scenic Ave, SPRINGFIELD, MO 65807-3926, United States. The biotechnology company can be reached via phone at +1-417-8834549 or via email at [email protected]
MarketBeat Community Rating for SLS International (AMEX SLS)
MarketBeat's community ratings are surveys of what our community members think about SLS International and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
